LiBo Pharma Corp.
↗New Taipei City, Taiwan
LiBo Pharma is a privately-held clinical-stage biopharmaceutical company founded in January 2017, headquartered in New Taipei City, Taiwan. The company specializes in developing protein therapeutics and oral drug delivery platforms addressing unmet clinical needs in Regenerative Medicine, Hematology, Oncology, and Immunology. LiBo operates using a virtual federated model where operations are outsourced and the company acts as a management hub coordinating partner activities, enabling efficient R&D execution with minimal overhead.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Therapeutic Proteins / Immunotherapy
SIZE & FINANCIALS
Employees:51-200
Revenue:Pre-revenue (clinical stage)
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series C+
Total Raised:NT$850 million (approximately USD $27-30 million equivalent)
Investors:LIH PAO GROUP (parent company), Taishin Venture Capital, CDIB Healthcare II Venture Fund, Capital Venture Management, CTBC Venture Capital, Qisda Group, Beiley Biofund, Zhongjia Investment, President International Development
STOCK
Exchange:TPEX (Taiwan)
Ticker:7888
PIPELINE
Stage:Phase 2/Phase 3
Lead Drug Stage:Phase 3 ready (CTCL indication), Phase 2 (DLBCL)
Modalities:Recombinant protein therapeutics, Cytokine immunotherapy, Oral drug delivery platforms
Active Trials:2
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:LIH PAO GROUP
Key Partnerships:Fukushima Medical University (investigator-initiated trial collaboration for HSARS/radiation medicine, initiated March 2026), BARDA (Biomedical Advanced Research and Development Authority - prior support for HSARS development)
COMPETITION
Position:Emerging
Competitors:ImmunityBio (IL-15 superagonist N-803), Kite Pharma (CAR-T cell therapy), Iovance Biotherapeutics (TIL therapy), BioNTech (mRNA-based immunotherapy), Other IL-12 therapeutic developers, Standard chemotherapy + radiation combination therapy
LEADERSHIP
Key Executives:
Dr. Henry Liu - Co-founder & CEO
Mandy M.-N. Lee - Co-founder & Director, Business Development & Licensing
Dr. Simon Hsieh - Chief Medical Officer
Kuanyin Lin - VP, Head of Business Development
Hugo Chang - Regulatory Affairs Associate Manager
Scientific Founders:Dr. Henry Liu (CEO, co-founder)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of LiBo Pharma Corp. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with LiBo Pharma Corp.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.